Hepion Pharmaceuticals to Present at NASH-TAG 2024

Rhea-AI Summary

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced the presentation of an abstract highlighting its lead drug candidate, rencofilstat, at the 2024 NASH-TAG Conference. The abstract showcases hepatic functional improvement detected by HepQuant DuO within 120 days of treatment with rencofilstat in NASH subjects with ≥F3 fibrosis. The presentation will be held on Saturday, January 6, 2024, and the materials will be accessible on the company's website.

EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented at the 2024 NASH-TAG Conference, which is being held January 4-6, 2024, in Park City, Utah.

Presentation Details

Title: Hepatic Functional Improvement Detected by HepQuant DuO within 120 Days of Treatment with Rencofilstat in MASH Subjects with ≥F3 Fibrosis.

Authors: SA Harrison, P Mayo, T Hobbs, C Zhao, C Canizares, R Foster, MP McRae, SM Helmke, and GT Everson

Date: Saturday, January 6, 2024

A copy of the presentation materials will be accessible on the Company’s website at www.hepionpharma.com under “Publications” in the Pipeline section.

About Hepion Pharmaceuticals

The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June 2022 by the FDA’s granting of Orphan Drug designation to rencofilstat for the treatment of HCC.

Hepion has created a proprietary Artificial Intelligence deep machine learning (“AI/ML”) platform designed to better understand disease processes and identify patients that are rencofilstat responders. This AI/ML has the potential to shorten development timelines and increase the observable differences between placebo and treatment groups. In addition, Hepion’s AI/ML can be used to drive its ongoing NASH and HCC clinical development programs and identify other potential therapeutic indications for cyclophilin inhibition with rencofilstat.

For further information, please contact:

Hepion Pharmaceuticals Investor Relations
732-902-4000

FAQ

What is the focus of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) focuses on AI-driven therapeutic drug development for the treatment of NASH, fibrotic diseases, HCC, and other chronic diseases.

What is the lead drug candidate of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)?

The lead drug candidate is rencofilstat, which is being highlighted in an abstract presentation at the 2024 NASH-TAG Conference.

Where will the presentation of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) be held?

The presentation will be held at the 2024 NASH-TAG Conference in Park City, Utah.

When will the presentation of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) take place?

The presentation will take place on Saturday, January 6, 2024.

Where can the presentation materials be accessed for Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)?

The presentation materials will be accessible on the company's website at www.hepionpharma.com under 'Publications' in the Pipeline section.